Skip to main content
Download PDF

Trehalose alleviates the phenotype of Machado–Joseph disease mouse models

Journal of Translational Medicine volume 18, Article number: 161 (2020) Cite this article

Abstract

Background

Machado–Joseph disease (MJD), also known as spinocerebellar ataxia type 3, is the most common of the dominantly inherited ataxias worldwide and is characterized by mutant ataxin-3 aggregation and neuronal degeneration. There is no treatment available to block or delay disease progression. In this work we investigated whether trehalose, a natural occurring disaccharide widely used in food and cosmetic industry, would rescue biochemical, behavioral and neuropathological features of an in vitro and of a severe MJD transgenic mouse model.

Methods

Two MJD animal models, a lentiviral based and a transgenic model, were orally treated with 2% trehalose solution for a period of 4 and 30 weeks, respectively. Motor behavior (rotarod, grip strength and footprint patterns) was evaluated at different time points and neuropathological features were evaluated upon in-life phase termination.

Results

Trehalose-treated MJD mice equilibrated for a longer time in the rotarod apparatus and exhibited an improvement of ataxic gait in footprint analysis. Trehalose-mediated improvements in motor behaviour were associated with a reduction of the MJD-associated neuropathology, as MJD transgenic mice treated with trehalose presented preservation of cerebellar layers thickness and a decrease in the size of ataxin-3 aggregates in Purkinje cells. In agreement, an improvement of neuropathological features was also observed in the full length lentiviral-based mouse model of MJD submitted to 2% trehalose treatment.

Conclusions

The present study suggests trehalose as a safety pharmacological strategy to counteract MJD-associated behavioural and neuropathological impairments.

Background

Machado–Joseph disease or spinocerebellar ataxia type 3 (MJD) is a polyglutamine neurodegenerative disorder first described in people of Portuguese descent. MJD is considered the most common of the dominantly inherited ataxias worldwide [1], with the highest prevalence reported in Azorean islands (1:239 in Flores, Portugal) [2]. MJD is caused by an expansion of the CAG trinucleotide in the coding region of the MJD1/ATXN3 gene, which is translated into a polyglutamine tract in the c-terminus of ataxin-3 protein. The mutation confers a toxic gain-of function to ataxin-3, with formation of neuronal intranuclear inclusions, neuronal dysfunction and degeneration [3,4,5]. Neuropathological alterations in MJD occur in the cerebellum, basal ganglia and brainstem and clinical features include progressive ataxia, ophtalmoplegia, dysarthria, dystonia, rigidity and distal muscle atrophies [1, 6, 7]. Progress towards understanding the pathogenesis of neurodegenerative disorders led to the identification of common pathological mechanisms and pathways in polyQ diseases that have become promising molecular targets for therapy. Over the last years, our group has focused on the study of autophagy in MJD and has identified this pathway as a relevant contributor to the neuropathology. We showed that autophagy is impaired in human brain tissue and fibroblasts of MJD patients and also in different animal and cellular models of MJD [8,9,10,11]. Moreover, upon local lentiviral-mediated expression of the autophagic protein 6/beclin-1 (Atg6/beclin-1) in the brain, we observed an alleviation of neuropathological and behavioral defects of MJD mouse models, evidencing that autophagy activation is a promising strategy to block MJD progression [8, 11]. However, these molecular approaches have limitations, particularly the risks associated to viral vector delivery and craniotomy. Moreover, the neuropathology of MJD involves multiple brain regions, so a strategy able to reach a broader distribution would be relevant. In an attempt to translate this strategy to the clinics in a short time-frame, we envisioned the systemic administration of a safe autophagy activator molecule as an advantageous alternative.

Trehalose, naturally present in several organisms, such as plants, yeasts, bacteria and invertebrates, is a non-reducing disaccharide, formed by two α-glucose molecules connected through an a,a-1,1 glycosidic linkage. It is currently used as a stabilizer in several food, cosmetic and pharmaceutical products, having an already proved safety profile [12, 13]. Trehalose has been reported to act as a natural autophagy inducer [14] and there is evidence of beneficial therapeutic effects of trehalose in relieving disease progression of protein aggregation diseases [15,16,17,18,19,20]. Nevertheless, no studies in MJD had yet been reported.

In this work, we designed a proof of concept study to assess whether trehalose alleviates behavioural and neuropathological phenotype features in MJD mouse models to evaluate the potential of this sugar to be used as a pharmacological drug to modify MJD disease progression.

Materials and methods

Drug

Trehalose was obtained from Pfanstiehl Inc (Illinois, USA) as trehalose dyhydrate, a white crystalline powder. In its solid form was stored at room temperature in a ventilated area. For in vitro and in vivo studies was prepared in water, as specified in the following sections.

Cell culture and treatments

The mouse neuroblastoma cell line (Neuro-2A cells) was obtained from the American Type Culture Collection cell biology bank (CCL-131) and maintained in Dulbecco’s modified Eagle’s medium (complete medium; Gibco) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin, at 37 °C in 5% CO2/air atmosphere. Neuro-2A transduction with lentiviral particles expressing mutant ataxin-3 72 CAG repeats (MutAtx-3) was performed as previously described [8]. Two weeks post-infection, cells were plated and treated with trehalose (1 mM, 10 mM or 100 mM) or control (vehicle) for 0.5 h, 1 h, 3 h, 6 h, 24 h, 48 h and 72 h. Treatments started 24 h after platting and medium was changed after 48 h. Trehalose incubations were repeated every 24 h and cells from all conditions were collected 72 h after platting.

Resazurin assay

Cells were incubated with 0.1 mg/mL resazurin solution, diluted 1:10 in DMEM culture medium, for 45 to 60 min at 37 °C. From each well, 100 µl triplicates were placed into a 96-well plate and the absorbance was read at wavelengths of 570 nm and 600 nm. The absorbance ratio 570/600 nm was calculated and expressed as percentage of control.

RNA extraction and RT-qPCR

Total RNA was extracted by using the NucleoSpin® RNA extraction kit, according to manufacturer’s instructions (Macherey–Nagel). RNA was eluted in 40 µl of nuclease-free water and total RNA was quantified by optical density (OD) using a Nanodrop 2000 Spectrophotometer (Thermo Scientific). RNA purity was evaluated by measuring the ratio of OD at 260 and 280 nm. 1000 ng of total RNA were treated with DNase (Qiagen) and then reverse transcribed into double stranded cDNA by using the iScript cDNA Synthesis Kit® (BioRad). cDNA samples were stored at − 20 °C until use.

Real-time PCR was performed using a standard SYBR-Green® PCR kit protocol on a StepOne® Detection System (Life Technologies). RT-PCR was carried out in 10 µL reaction, which included cDNA product (diluted 1:10), 1× SsoAdvanced SYBR Green Supermix and 0.5 µM of forward and reverse primers. Primers for SIRT1, LC3B, p62 and Beclin-1 were pre-designed and validated by QIAGEN (QuantiTect Primers, QIAGEN). Primers for mutant ataxin-3 and HPRT-1 were designed and validated by our group. Reverse-transcription and non-template controls were run in parallel. All reactions were performed in duplicate, according to the manufacturer’s recommendations: 95 °C for 30 s, followed by 45 cycles at 95 °C for 5 s and 60 °C for 30 s. HPRT-1 was used as reference gene. The mRNA fold increase or fold decrease with respect to control samples was determined by the delta-delta Ct method.

Animals and experimental groups

Transgenic mouse model

A colony of MJD transgenic mice (MJDTg; C57BL/6 background) expressing the N-terminal-truncated human ataxin-3 with 69 glutamine repeats and a N-terminal hemagglutinin (HA) epitope, driven specifically in cerebellar Purkinje cells by the L7 promoter [21], was maintained at CNC animal facility by backcrossing heterozygous males with C57BL/6 females. For this experiment, 14 MJD transgenic female mice were weaned and genotyped at 4 weeks of age. Females have a less aggressive phenotype than males (unpublished data) and were therefore used in this experiment to avoid the use of weakened animals that could reach the humane critical endpoints over the long course of the experiment. Animals were housed in groups (2–5 per cage, depending on cohort study) in plastic cages (365 × 207 × 140 mm) with food and water ad libitum, and maintained on a 12-h light/dark cycle at a room with constant temperature (22 ± 2 °C) and humidity (55 ± 15%). The animals were allowed 1 week of acclimation to the surroundings before the beginning of the behavioral tests. Physical state of animals was evaluated daily and weight measured every week.

MJD Tg mice from different progenitors were randomly distributed into control and treatment group (7 animals/group) and then tested for behavior background before beginning the treatment. Trehalose was orally administered diluted in drinking distilled water at a final concentration of 2% (w/v) to the treatment group, from week 5 to week 35 of age. The control group was treated with vehicle (distilled water). A fresh solution of 2% Trehalose in water was prepared and changed twice a week until euthanasia of the animals.

Lentiviral-based mouse model

Twenty-five C57/Bl6 mice (Charles River, France), males, 8 weeks old, were housed in groups of 6 per cage, in plastic cages (365 × 207 × 140 mm) with food and water ad libitum, and maintained on a 12-h light/dark cycle at a room with constant temperature (22 ± 2 °C) and humidity (55 ± 15%). Males were used in this experiment to ensure comparability with previous studies using this model. The animals were stereotaxically-injected in the striatum with lentiviral vectors encoding mutant human ataxin-3 with 72 CAG repeats, as previously described [22]. After recovery from surgery, mice were randomly distributed into control (n = 13) and treatment groups (n = 12). The treatment group was orally-administered with trehalose diluted in drinking water at a final concentration of 2% (w/v) and the control group was treated with the vehicle (water). After 2 and 4 weeks of drug administration, mice were euthanized and brains collected for analysis (western bot and immunohistochemistry, respectively).

Behavioral testing

Mice were trained on a battery of motor tests starting at 4 weeks of age (P21–25) and tested for behavioural background at 5 weeks of age (before the beginning of trehalose treatment, t = 0). Behaviour was then evaluated at different time points (t = 2, t = 6, t = 11, t = 14, t = 17, t = 20, t = 24 and t = 28 weeks of treatment) by an experienced operator in a blind fashion way. All tests were performed in the same dark room after at least 60 min of acclimatization.

Rotarod performance test

Motor coordination and balance were evaluated in a rotarod apparatus (Letica Scientific Instruments, Panlab, Barcelona, Spain). Mice were placed on the rotarod at a constant speed (5 rpm) and at accelerated speed (4 to 40 rpm in 5 min) and the latency to fall was recorded for a maximum of 5 min. Mice were allowed to perform four trials for each test and time point, with at least 30 min rest between trials. For analysis, the mean latency to fall off the rotarod of 4 trials was used.

Grip strength test

A grip strength test was performed to assess mice neuromuscular function. The grip strength of forelimbs was determined using a device consisted of a 300-g metal grid with a scale on. The animal was hung with its forepaws on the grid. The strength was determined as the weight pulled (g) from the scale. The test was performed during 10–15 consecutive trials and the mean of four best performances was taken to analysis. Mice body weight was used as a normalization factor.

Footprint analysis

Footprint analysis was performed at 28 weeks post-initiation of treatment. To obtain footprint patterns, mice front and forefeet were coated with blue and red non-toxic paints, respectively. Mice were allowed to walk on a blank greenish paper along a 100 cm long, 10 cm wide runway (with 15 cm high walls). Stride length was measured as the average distance of forward movement between each stride. Frontbase width and hindbase width were measured as the average distance between left and right front and hind footprints, respectively. These values were determined by measuring the perpendicular distance of a given step to a line connecting its opposite preceding and proceeding steps. The distance from left or right front footprint/hind footprint overlap was measured to evaluate uniformity of step alternation. A sequence of five consecutive steps was chosen for evaluation, excluding footprints made at the beginning and at the end of the run. Measurements were all made by the same operator. The mean value of each set of five was considered for each animal.

Brain tissue collection

For histological analysis, the animals were given an avertin overdose (2.5 × 200 mg/g, i.p.) and were transcardially perfused with a phosphate solution (0.1 M) followed by fixation with 4% paraformaldehyde (PFA; Fluka, Sigma, Buchs, Switzerland). The brains were removed, post-fixed in 4% PFA for 24 h at 4 °C, and then cryoprotected by immersion in 25% sucrose/phosphate buffer for 48 h at 4 °C. The brains were frozen at − 80 °C and then the entire cerebellum (transgenic model) or brain (lentiviral-based model) was sliced into 30-μm midsagittal or 25-μm coronal sections, respectively, using a cryostat (LEICA CM3050S, Leica Microsystems) at − 21 °C. Sections were collected in anatomical series and stored at 4 °C as free-floating sections in phosphate buffered saline (PBS) supplemented with 0.05 mM sodium azide until processing.

For western blot analysis (lentiviral-based model), animals were euthanized by cervical dislocation. Tissue punches from striatum were collected and keep at -80 °C until use.

Histological analysis of brain tissue

Cresyl violet staining

Eight sagittal sections along the extent of the mice left hemicerebellum (inter-section distance of 240 µm, which corresponds to eight sections of 30 µm) were mounted in gelatin covered microscope slides and dried at room temperature. Sections were then stained with cresyl violet for 5 min, differentiated in 70% ethanol, dehydrated by passing through 95% ethanol, 100% ethanol and xylene solutions and mounted with Eukitt (Sigma-Aldrich).

Immunofluorescent staining

Immunofluorescent staining was performed in eight sagittal sections over the extent of the mice left hemicerebellum (inter-section distance of 240 µm, which corresponds to eight sections of 30 µm). Free-floating sections were washed with PBS 0.1 M and blocked for 1 h at room temperature in 0.3% Triton X-100 in PBS 0.1 M supplemented with 10% normal goat serum (NGS; Gibco). Sections were then incubated with the following primary antibodies: mouse monoclonal anti-HA antibody (1:1000; InvivoGen, San Diego, CA, USA) and rabbit polyclonal anti-calbindin-28 K antibody (1:1000; Merck Millipore) overnight at 4 °C. After incubation, sections were washed three times with PBS and then incubated with the corresponding secondary antibody goat anti-mouse conjugated to the fluorophore 488 (1:200; Molecular Probes, Oregon, USA), diluted in blocking solution, for 2 h, at room temperature. Finally, sections were washed three times in PBS, counterstained with 4′,6-diamidino-2-phenylindole, washed again and mounted with Fluorsave (Calbiochem, Germany).

Immunohistochemistry

Immunohistochemistry was performed in twelve coronal sections covering the extent of the mice striata (25 μm-thick sections at 200 μm intervals). After the blockage of endogenous peroxidases with phenylhidrazyne/phosphate solution, free-floating sections were washed with PBS 0.1 M and blocked for 1 h at room temperature in blocking solution (0.1% Triton X-100 in PBS 0.1 M supplemented with 10% normal goat serum). Sections were processed overnight at 4 °C in blocking solution with the following primary antibodies: a polyclonal rabbit anti-ubiquitin antibody (1:300; Enzo Life Sciences) and a polyclonal rabbit anti–DARPP-32 antibody (1:1000; Merck Millipore), followed by 2-h incubation at room temperature with the respective biotinylated goat anti-mouse or anti-rabbit antibodies (1:200; Vector Laboratoires). Bound antibodies were visualized using the Vectastain ABC kit, with 3,30-diaminobenzidine tetrahydrochloride (DAB metal concentrate, Pierce) as substrate. Dry sections were mounted in gelatin-coated slides, dehydrated with ethanol solutions and xylene and mounted in Eukit (Sigma-Aldrich).

Quantitative analysis of histological sections

Quantification of cerebellum volume (transgenic model)

Quantification was made over eight cresyl violet staining sagittal sections over the extent of the mice left hemicerebella in a blind fashion. Mosaic pictures of these sections were taken using a PALM Laser microdissection microscope (Carl Zeiss, Germany) with a 20× objective. Volume was assessed by measuring the area of the cerebellum in each section using Fiji software. Hemicerebellum final volume was extrapolated using the following formula: volume = (area × section thickness) × number of sections.

Quantification of cerebellum layers thickness (transgenic model)

Quantification was made over four cresyl violet-stained sagittal sections. Mosaic pictures were taken using a PALM Laser microdissection microscope (Carl Zeiss, Germany) with a 20× objective. For each section, layers length was blindly determined using Fiji software. Layers thickness was assessed by measuring the mean width of cerebellum layers (molecular + granular + Purkinje cell layers) at interlobular regions.

Quantification of Purkinje cells and mutant ataxin-3 aggregates (transgenic model)

Quantitative analysis of number of Purkinje cells (calbindin-positive cells) and mutant ataxin-3 aggregates (HA aggregates) was performed over eight sections. To calculate the number of calbindin-positive cells, mosaic pictures were taken using a PALM Laser microdissection microscope (Carl Zeiss, Germany) with a 20× objective. Images were visualized with ImageJ software and cells were then manually counted by an operator in a blind fashion. Total number (no) of purkinje cells per hemicerebellum was calculated by extrapolation, using the formula:

$${\text{no}}\;{\text{of}}\;{\text{purkinje}}\;{\text{cells}}\, = \,\left( {{\text{no}}\;{\text{of}}\;{\text{cells in section 1}}\, + \,{\text{no of cells in}}\;{\text{section}}\;2\, + \, \cdots \, + \,{\text{no of cells}}\;{\text{in}}\;{\text{section}} \; 8} \right) \times 8 {\text{ sections}}$$

Total number of HA aggregates was manually counted by an operator in a blind fashion by visualizing immunostained sections using a Axioskop 2 plus microscope (Carl Zeiss) and calculated by extrapolation, using the formula:

$${\text{no of mutant ataxin{-}3 aggregates}}\, = \,\left( {{\text{no of aggregates in section 1}}\, + \,{\text{no of aggregates in}}\;{\text{section 2}} + \cdots + {\text{no of aggregates in}}\;{\text{section 8}}} \right) \times 8 {\text{ sections}}$$

Quantification of mutant ataxin-3 aggregates size (transgenic model)

Quantitative analysis of mutant ataxin-3 aggregates size was performed over four sections. Three representative pictures of lobule IX were taken using a Cell Observer Spinning Disk (Carl Zeiss, Germany) with a 100× objective. Z projections were visualized and the diameter was manually determined by an operator in a blind fashion using Fiji software.

Quantification of DARPP-32 depleted volume, ubiquitin inclusions number and size (lentiviral model)

Quantification was made over twelve coronal sections per animal (25 μm-thick sections at 200 μm intervals) on the extent of the mouse striatum, in a blind fashion. Pictures of DARPP-32 stained sections were taken using a 5× objective using an Axioskop 2 Plus microscope (Carl Zeiss, Germany). Volume was assessed by measuring the area of the lesion in each section using Fiji software. Final volume was extrapolated as described above. Pictures of ubiquitin-stained sections were taken using a 20× objective, with the same microscope. The analyzed areas of the striatum encompassed the entire region containing ubiquitin aggregates. All inclusions were blindly automatically counted using Fiji software. Total number of ubiquitin aggregates was extrapolated as described for ataxin-3 aggregates. Data were normalized to the integrated lentivirus copy number, quantified as described below.

Protein extraction and preparation

Cellular extracts were obtained by scrapping cells with radioimmunoprecipitation assay (RIPA) buffer solution [50 mM Tris·HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulfate (SDS)] supplemented with protease inhibitors (Roche), 200 μM phenylmethylsulphonylfluoride, 1 mM dithiothreitol (DTT), 1 mM Na3VO4 and 10 mM NaF.

Tissue extracts were lysed in RIPA buffer, supplemented as described above, by 2 series of 4 s ultra-sound pulse (1 pulse/s). Total protein lysates were stored at − 20 °C and protein concentration was quantified with BCA protein assay (Pierce Biotechnology, Thermo Scientific, USA).

Western blotting

Protein samples were denaturated in SDS sample buffer (0.5 M Tris, 30% glycerol, 10% SDS, 0.6 M DTT, 0.012% bromophenol blue) for 5 min at 95 °C. Samples were then separated in a 4–12% SDS–polyacrylamide gel electrophoresis (SDS-PAGE). Ponceau S staining was performed after transference and the membranes were blocked with 5% non-fat milk in TBS-T (137 mM NaCl, 20 mM Tris, 0.1% Tween 20, pH 7.6) following by incubation overnight at 4 °C with mouse monoclonal anti-β-actin antibody (clone AC74;1:5000; Sigma-Aldrich), mouse monoclonal anti-β-tubulin antibody (clone SAP.4G5;1:10,000; Sigma-Aldrich), mouse anti-GAPDH (1:500; Merck Millipore), mouse monoclonal anti-HA antibody (1:1500; InvivoGen, San Diego, CA, USA), rabbit monoclonal anti-p62 antibody (1:1500; Cell Signaling Technology) and rabbit monoclonal anti-LC3B antibody (1:1000; Cell Signaling Technology) diluted in blocking solution or in 3% bovine serum albumin (for cell signaling antibodies). After three washes with TBS-T, the membranes were incubated for 1 h, at room temperature, with an alkaline phosphatase-linked secondary antibody, specific to rabbit or mouse immunoglobulin G (1:20,000, Amersam Biosciences, GE Healthcare, UK). Immunoreactive bands were visualized using enhanced chemifluorescence (ECF) substrate in the Versa-Doc 3000 imaging system (Bio-Rad, USA) and densitometry of the bands was quantified using ImageJ software. The specific optical density was normalized to the total protein, measured by ponceau S, or to the amount of β-actin [23].

Integrated lentivirus copy number quantification

Twelve mounted histological slides were immersed in xylene for 2 days and then hydrated with ethanol solutions and water. Lentiviral-injected striata were removed with a scalpel and DNA extraction was performed using the GeneRead DNA FFPE Kit (Qiagen), starting from step 6 of manufacturer’s protocol. Purified cellular genomic DNA was then quantified by optical density (OD) using a Nanodrop 2000 Spectrophotometer (Thermo Scientific) and the purity was evaluated by measuring the ratio of OD at 260 and 280 nm. Copy number of integrated lentiviruses (proviruses) present in the transduced cells of striatum was detected by qPCR using the Lenti-X Provirus Quantitation Kit (Takara) and according to the manufacturer’s instructions. Briefly, serial dilutions of the cellular gDNA were subjected to qPCR amplification alongside dilutions of a calibrated Provirus control template. The final result was expressed in terms of provirus copies (vg)/cell.

Statistical analysis

Raw data analysis was conducted using Prism GraphPad software. Outliers were excluded from analysis using Grubb’s test. For behavior results, mean values for each animal were calculated and a two-tailed Student’s t test (footprint analysis) or a trend analysis to compare linear regression slopes using the two-tailed t test hypothesis (other behavioral tests) was performed. For other analysis, statistics was performed using the two-tailed Student’s t test. Data were represented as mean ± SEM.

Results

Trehalose activates autophagy and reduces mutant ataxin-3 protein levels in neuro-2a cells expressing mutant ataxin-3

We previously showed that autophagy is compromised in MJD and that its activation can ameliorate the disease neuropathology [8, 11]. To investigate the ability of trehalose to increase autophagy in MJD we used Neuro 2A cells expressing the human isoform of MutAtx3, a previously described in vitro model of MJD [8]. We first observed that trehalose could be used to treat these cells up to 10 mM concentration for a period of 72 h without changing metabolic activity (Additional file 1: Fig. S1). Cells were then incubated with 10 mM trehalose for 0.5, 1, 3, 6, 24, 48 and 72 h, and the levels of the transient autophagosomal membrane-bound form of LC3B (LC3BI and LC3BII), a marker of the autophagic process, were measured by western blot. As shown in Fig. 1a, b, LC3BII protein levels significantly increased after 24 h, 48 h and 72 h treatment with 10 mM trehalose, when compared to control. More relevant, this effect was accompanied by a significant decrease in protein levels of mutant ataxin-3 (Fig. 1a, b; Additional file 2: Fig. S2 and Additional file 3: Fig. S3). Transcript levels of mutant ataxin-3 and autophagy markers (LC3B, p62 and beclin-1) did not change after 10 mM trehalose treatment for a period of 72 h (Additional file 4: Fig. S4).

Fig. 1
figure1

Autophagy activation by trehalose in neuro-2A cells expressing mutant ataxin-3. Neuro-2A cells expressing mutant ataxin 3 (MutAtx-3) were treated with 10 mM trehalose or vehicle (control) from 0.5 to 72 h (h). Protein levels of LC3BI, LC3BII, endogenous ataxin-3 (EndAtx-3) and mutant ataxin-3 (MutAtx-3) were quantified by western blot. a Representative picture of Western blot. b Quantitative densitometric analysis of western blot bands. Values are presented as mean ± SEM (n = 4–5). Results are expressed as % of control. *,#, $p < 0.05; **,##, $$p < 0.01, compared to control. One-way analysis of variance (ANOVA), followed by a Dunnett’s post hoc analysis for multiple comparisons; outliers were excluded using the Grubb’s test. Cells were then incubated for 72 h with trehalose 10 mM, in the presence and absence of the lysosomal degradation inhibitor, chloroquine, for 6 h before protein collection. Protein levels of LC3BII were quantified by western blot. c Representative picture of Western blot. d Quantitative densitometric analysis of western blot bands. Values are presented as mean ± SEM (n = 6). Results are expressed as % of control. ##p < 0.01, compared to control; Student’s t test. ****p < 0.0001, compared to control; One-way analysis of variance (ANOVA), followed by a Dunnett’s post hoc analysis for multiple comparisons. e Autophagic flux quantification by the LC3BIIturnover assay. Difference between densitometric intensity of LC3II bands between control and trehalose conditions in the presence and absence of lysosomal inhibitors. Values are presented as mean ± SEM (n = 6). +p<0.05, compared to control plus chloroquine; Student’s t test

Full size image

Increased levels of LC3BII do not necessarily indicate an increase in total autophagic flux as it can also be a consequence of impaired autophagosome-lysosome fusion [24]. LC3BII is degraded at the final stages of autophagy and when lysosomal degradation is blocked there is an accumulation of this protein. Accumulation of this protein upon lysosomal degradation inhibition is indicative of increased autophagic flux. To confirm whether trehalose was indeed increasing autophagy, we evaluated LC3BII protein levels in the presence and absence of chloroquine, an inhibitor of lysosomal degradation. Again, an increase in LC3BII protein levels was observed in N2A cells expressing MutAtx-3, after 72 h treatment with 10 mM trehalose, as compared with control condition (Fig. 1c, d; ##p < 0.01). Moreover, upon lysosomal degradation inhibition with chloroquine 100 µM for 6 h, an accumulation of LC3BII was observed for both control and trehalose conditions, respectively (Fig. 1d; ****p < 0.0001, compared to control). More important, an increased accumulation of LC3BII was observed in 10 mM trehalose plus chloroquine condition, when compared to control plus chloroquine (Fig. 1d; +p<0.05, compared to control), further indicating that trehalose increased autophagic flux. We next determined autophagic flux by the LC3BII turnover assay, which compares the LC3II protein levels between control and trehalose conditions in the presence and absence of lysosomal inhibitors (LC3BII net flux) [25]. As shown in Fig. 1e, 10 mM trehalose increased LC3BII autophagic flux in neuro-2A cells expressing mutant ataxin-3, indicating an activation of autophagy. Altogether, these data shows that trehalose activates autophagy and reduces mutant ataxin-3 levels in this in vitro model of MJD.

Trehalose alleviates motor deficits in MJD transgenic mice

Building on the obtained in vitro results, we designed an in vivo experiment to investigate whether administration of trehalose to a transgenic mouse model of MJD would alleviate behavioral and neuropathological defects. Fourteen MJD transgenic female mice were distributed into control and treatment groups and a 2% trehalose solution was orally administered to the treatment group over a period of 30 weeks (Fig. 2). Dose was chosen accordingly to previous studies in animal models of protein aggregation diseases [17, 20]. Mice body weight and general physical health was evaluated each week until euthanasia of animals. Throughout the whole study, trehalose had no effect in body weight and caused no apparent impact in mice general health (Additional file 5: Fig. S5).

Fig. 2
figure2

Study design for the transgenic MJD model. Fourteen MJD transgenic female mice were weaned and genotyped at 4 weeks old. MJD transgenic mice were then randomly distributed into Treatment and Control groups that received either 2% Trehalose in drinking water or fresh distilled water, respectively, from 5 weeks up to 35 weeks of age. Motor and neuromuscular function of the animals was evaluated by performing rotarod (constant and accelerated speed) and grip strength tests, respectively, before the beginning of Trehalose treatment (5 weeks of age; t = 0) and at several time points (t = 2, t = 6, t = 11, t = 14, t = 17, t = 20, t = 24, t = 28 weeks of treatment). The footprint analysis was performed only at t = 28 weeks of treatment. The animals were sacrificed at 35 weeks of age (t = 30) and brain tissues were collected for histopathological analysis of the cerebellum

Full size image

To evaluate the therapeutic potential of trehalose in recovering the balance and motor function deficits of MJD transgenic mice, we performed the rotarod test. Behavioural testing evaluation started before the beginning of the treatment (5 weeks old; t = 0 weeks of treatment) and was repeated at different time points until 28 weeks of trehalose administration (Fig. 2). A linear regression analysis was used to assess the time course of behavioral performance [26]. At 5 weeks of age, MJD transgenic mice already present a marked phenotype characterized by ataxic movement and difficulty to walk and equilibrate, as previously described [9, 21, 27]. Trehalose administration improved motor performance of MJD transgenic females, as shown by the increase in time that treated females equilibrated in rotarod apparatus, compared to control animals, which over time exhibited a decrease in the latency time to fall (Fig. 3a, b). This effect was statistically significant for stationary rotarod performance test [Linear regression slopes for stationary rotarod: Control = − 0.6082 ± 0.3820, 2% trehalose = 0.8690 ± 0.3620, p = 0.0058, (Fig. 3a); Linear regression slopes for accelerated rotarod: Control = − 0.4599 ± 0.1863, 2% trehalose = − 0.1966 ± 0.1519; p = 0.2756).

Fig. 3
figure3

Motor and neuromuscular function of MJD transgenic mice treated with 2% Trehalose. MJD transgenic females were randomly distributed into control (n = 7; black) and treatment groups (n = 7; green) and orally treated either with vehicle or 2% Trehalose. Rotarod and grip strength tests were done before the beginning of the treatment and at different time points until 28 weeks (a, b, d). Statistical analysis was performed comparing linear regression slopes by a two-tailed t test hypothesis. In rotarod tests, 2% Trehalose increased the latency time to fall of MJD transgenic females (a, b). No statistically significant differences in forelimb strength were observed between control and 2% Trehalose groups (d). Additionally, footprint patterns were evaluated 28 weeks after treatment (c). Statistical analysis for footprint was performed by using the Student’s t test hypothesis. 2% Trehalose reduced gait deficits of MJD transgenic females, increasing the stride length and decreasing the frontbase distance (c). Data are presented as mean ± SEM, * < 0.05; ** < 0.01; ns = not significant, comparing to controls

Full size image

MJD transgenic mice also exhibit significant gait deficits, presenting reduced stride length and enlarged front and hindbase, which can be evaluated by analysis of footprint patterns [11]. Therefore, at 28 weeks of treatment, a footprint analysis was additionally performed to investigate whether trehalose could rescue limb and gait ataxia of MJD transgenic mice. As shown in Fig. 3c a close to significant increase in the stride length (Control = 6.02 ± 0.12 cm, 2% trehalose = 6.51 ± 0.18 cm, p = 0.052, Student’s t test) and a significant decrease in the front base width (Control = 2.01 ± 0.08 cm, 2% trehalose = 1.77 ± 0.07 cm, p = 0.047; Student’s t test) was observed in MJD transgenic females treated with 2% trehalose, revealing that trehalose reduced the gait deficits of MJD transgenic females. Overall, behavioural data show that 2% trehalose treatment alleviates motor and coordination deficits in MJD transgenic mice.

The neuromuscular function is also affected in MJD patients, since the primary function of the cerebellum is to maintain the excitability of the motor cortex and the subsequent control of movement [28]. Such as in clinical observations in patients, MJD transgenic mice display significant strength deficit [22]. Therefore, we performed the grip strength test to assess the ability of trehalose in recovering neuromuscular deficits, but no statistically significant differences in forelimb strength were observed between groups (Linear regression slopes: Control = − 0.0345 ± 0.0057, 2% trehalose = − 0.0422 ± 0.0058; p = 0.3470), suggesting that trehalose had no effect in recovering neuromuscular function of this MJD transgenic mouse model.

Trehalose reduces cerebellar atrophy and mutant ataxin-3 aggregate size in Purkinje cells of Machado–Joseph disease transgenic mice

Cerebellar atrophy is an important neuropathological hallmark of this MJD animal model [11, 21], as it is typically present in MJD patients [29]. To evaluate if the phenotypic improvement correlated with preservation of the cerebellar neuroanatomy we performed the Nissl staining with cresyl violet, which is a classical histological method widely used to study the cytoarchitecture of brain areas [30, 31]. The total cerebellar volume and cerebellar layers thickness were measured. Despite no observation of differences between groups for cerebellar volume (Fig. 4b; Control = 4.67 ± 0.15 mm3; 2% trehalose = 4.68 ± 0.13 mm3; p = 0.9664), cresyl violet staining revealed larger thickness (Fig. 4a, b; Control = 167.3 ± 2.1 µm, 2% trehalose = 176.3 ± 3.1 µm, p = 0.0342) of cerebellar layers of treated MJD transgenic mice, when compared to controls (Fig. 4c), suggesting prevention of neurodegeneration by trehalose.

Fig. 4
figure4

Neuropathological analysis of brain tissue from MJD transgenic mice treated with 2% Trehalose. Cresyl violet staining was performed on left hemicerebellum sections from MJD transgenic female mice treated with distilled water (control; n = 7) or 2% Trehalose (n = 7) for 30 weeks. a Representative picture of cerebellum layers from control and 2% Trehalose-treated MJD transgenic mice. Abbreviations: GL, Granular layer; ML, Molecular layer; PCL, Purkinje cell layer. Scale = 50 µm. b, c Trehalose has no effect in cerebellum volume, but increased the thickness of cerebellum layers compared to controls. Data are presented as mean ± SEM. Statistical analysis was performed using the two-tailed Student’s t test. * < 0.05, comparing to controls; ns = not significant. Immunofluorescent staining was also performed on left hemicerebellum sections from MJD transgenic mice treated with distilled water (control; n = 7) or 2% Trehalose (n = 7) for 30 weeks. d Representative confocal image of immunofluorescent staining against HA (MutAtx-3; green) and calbindin (red) of left hemicerebellum sections from MJD transgenic mice treated with distilled water (control; n = 7) or 2% Trehalose (n = 7) for 30 weeks. Scale bar = 10 µm. e Representative picture of aggregates size from control and 2% Trehalose-treated MJD transgenic mice. Scale bar = 5 µm. f, g The total number of aggregates and aggregates size (diameter) in a representative lobule (lobule IX) were quantified. Trehalose had no effect in total number of aggregates, but decreased aggregates diameter in lobule IX. Data are presented as mean ± SEM. Statistical analysis was performed using the two-tailed Student’s t test. ns not significant

Full size image

Mutant ataxin-3 has toxic properties due to the expanded polyQ tract, aggregating and accumulating in neuronal cells [3, 4]. As shown in Fig. 4d, and previously described [9, 21], neuronal inclusions accumulate in Purkinje cells of the cerebellar cortex in this transgenic mouse model. Purkinje cells were stained against calbindin-28 K, commonly used as Purkinje cell marker, but a very weak and diffuse immunofluorescent signal was observed in mice at this age (35 weeks old), particularly in controls (Fig. 4d). This loss of calbindin staining is associated with neuronal dysfunction of Purkinje cells [32]. As can be observed, Purkinje cells presented with irregular cell bodies and a disordered dendritic network. When treated with 2% trehalose, an improvement of the immunofluorescent pattern was observed, and Purkinje cellular bodies were less irregular and the dendritic network more preserved (Fig. 4d).

We then investigated whether trehalose could modify the number and the size of mutant ataxin-3 aggregates in the cerebellum of MJD transgenic mice. This mouse model expresses a NH2-truncated form of the ataxin-3 protein (with Q69), that lacks the 286 NH2-terminal amino acid residues, but is tagged by an HA epitope [21], so an immunostaining for the HA tag was performed to measure aggregation. The total number of mutant ataxin-3 aggregates in the whole cerebellum was counted but no differences were observed between 2% trehalose and control MJD transgenic mice (Fig. 4f, Control = 6115 ± 865; 2% trehalose = 6233 ± 419; p = 0.9041). However, we observed that trehalose significantly decreased the diameter of mutant ataxin-3 aggregates in a representative lobule (lobule IX) of the cerebellum (Control = 1.91 ± 0.03 µm; 2% trehalose = 1.80 ± 0.03 µm; p = 0.0197; Fig. 4e, g). These results show that trehalose alleviates cerebellar neuropathology of this transgenic mouse model of MJD.

Trehalose ameliorates neuropathology of a lentiviral-based mouse model of MJD

To further strengthen the results obtained with the transgenic model, we used a striatal lentiviral-based mouse model of MJD to evaluate whether trehalose could alleviate neuropathology. In this model, the neuropathological features of MJD are induced by the injection of lentiviral vectors encoding a full-length human mutant ataxin-3 carrying 72 CAG repeats [22]. Twenty-five mice were injected in the striatum with the lentiviral vectors and distributed into control (n = 13) and treatment groups (n = 12), which were orally administered with water and 2% trehalose solution, respectively. Accordingly to previously studies from our group [22, 33], we expected to observe a positive effect of the treatment after 4 weeks administration, which would rationally be anticipated by an increase in autophagy. Thus, half of the animals (6 controls and 6 treated mice) were sacrificed after 2 weeks to evaluate autophagy markers and the other half (7 controls and 6 treated mice) after 4 weeks to evaluate neuropathology, by western blot and immunohistochemistry, respectively (Fig. 5). After 2 weeks administration of 2% trehalose, no statistically significant differences in LC3BII and p62 protein levels were detected between groups (Fig. 6a, b, (Additional file 7: Fig. S7). At this time point, levels of mutant ataxin-3 (aggregates, oligomers and soluble form) were also similar in animals administered with water and 2% trehalose (Additional file 6: Fig. S6).

Fig. 5
figure5

Study design for the lentiviral based MJD model. Twenty-five C57/Bl6 mice, males, 8 weeks old, were stereotaxically-injected in the striatum with lentiviral vectors encoding mutant human ataxin-3 with 72 CAG repeats. Mice were then randomly distributed into treatment (n = 12) and control groups (n = 13) that received either 2% Trehalose in drinking water or fresh distilled water, respectively, After 2 and 4 weeks of drug administration, mice were euthanized and brains collected for analysis

Full size image
Fig. 6
figure6

Brain tissue analysis of the lentiviral-based mouse model treated with 2% Trehalose. C57/Bl6 mice, males, 8-weeks old, were stereotaxically-injected bilaterally in the striatum with lentiviral vectors encoding mutant human ataxin-3 with 72 CAG repeats and distributed into control and treatment groups that received either water or 2% Trehalose, respectively, during 2 weeks. Protein levels of autophagy markers were quantified by western blot in both left and right striatal punches. a Picture of western blot membranes. b Quantitative densitometric analysis of autophagy markers (p62 and LC3BII) western blot bands. Values are presented as mean ± SEM (n = 12–13 striatum per group from 6 to 7 animals). Student’s t test, compared to control. Loss of darpp-32 staining and ubiqutitin aggregates were evaluated by immunohistochemistry, after 4 weeks of 2% trehalose administration, in mice stereotaxically-injected unilaterally in the striatum with mutant human ataxin-3 encoded lentiviral vectors. c Representative figure of darpp-32 immunohistological staining. Scale = 100 µm. d The darpp-32 depleted immunoreactivity was decreased in mice treated with 2% trehalose. Data are presented as mean ± SEM. Statistical analysis was performed using the two-tailed Student’s t test. *p < 0.05, compared to control. e Representative picture of ubiquitin staining. Scale bar = 50 µm. f, g Trehalose had no statistically significant effect in total aggregates number and size, but a tendency for decrease was observed. Data are presented as mean ± SEM. Statistical analysis was performed using the two-tailed Student’s t test. ns = not significant

Full size image

Histologically, this mouse model is characterized by the presence of ubiquitinated aggregates and the loss of Darpp-32 immunoreactivity [22, 33]. Darpp-32 is a protein of the dopaminergic signaling pathway and loss of its immunoreactivity is indicative of early neuronal dysfunction. The darpp-32-depleted area in histological sections is thus used to quantify the neuropathological defects induced by mutant ataxin-3 expression. After 4-weeks administration of 2% trehalose, treated mice had a smaller lesion in the striatum, when compared to control animals (AreaControl = 52.89 ± 10.88 µm2/vg/cell; AreaTreatment = 25.56 ± 2.87 µm2/vg/cell; p = 0.0454; Fig. 6c, d). Despite no statistically-significant differences between groups regarding the aggregate number (Control = 4842 ± 1290; 2% trehalose = 3125 ± 395; p = 0.2608; Fig. 6e), trehalose showed a tendency to decrease the aggregates area (AreaControl = 1.282 ± 0.337 µm2/vg/cel; AreaTreatment = 0.719 ± 0.075 µm2/vg/cel; p = 0.1591; Fig. 6f, g), indicative of a reduced aggregates size. These observations reveal a protective effect of trehalose regarding neuropathologic features that characterize this lentiviral model of MJD.

Discussion

In the present work, we show that administration of trehalose alleviates the phenotype of two mouse models of MJD, suggesting trehalose may be a potential pharmacological candidate for MJD.

It has been shown that trehalose acts as an autophagy inducer [14] and as a chemical chaperone preventing protein misfolding and aggregation [34]. These properties have pointed towards the use of trehalose for the treatment of protein aggregation disorders. Therapeutic effects of trehalose have been reported in a number of diseases using both in vitro and in vivo models, but not in MJD [35].

Before testing trehalose in vivo, we investigated whether trehalose would be able to activate autophagy in an in vitro model of MJD. This in vitro model was generated by expressing an expanded form of human ataxin-3 in mouse neuroblastoma cells [8]. We observed a time-dependent activation of autophagy by trehalose, with a remarkable effect after 24 h, 48 h and 72 h treatment at a concentration of 10 mM. The activation of autophagy parallels the decrease in the mutant ataxin-3 protein, showing that trehalose is effective in reducing mutant protein levels. These results are in accordance with previously described time-dependent effects of trehalose in reducing aggregated proteins through autophagy activation in neuronal cell models of Prions’s [15], Parkinson’s and Huntington’s diseases [14].

Based on the in vitro results, we pursued a study using an animal model expressing a truncated form of human ataxin-3 in Purkinje cells of the cerebellum [21]. The cerebellum is one of the most affected brain regions in MJD, being essential for motor coordination and balance [36]. Dysfunction and death of cerebellar Purkinje cells lead to degeneration of connected cells present in other cerebellar layers and consequently to cerebellar atrophy, which is particularly marked in this animal model [21]. These MJD transgenic mice display a severe cerebellar ataxic behaviour with pronounced impairments in coordination, balance and gait patterns since the 3rd week of age [9, 11, 21]. When animals were administered with 2% trehalose we observed beneficial therapeutic effects in motor behaviour of the transgenic mouse model. This is particularly relevant considering the aggressive phenotype presented by these mice and the fact that trehalose administration started at 5 weeks of age, after the onset of the disease. Furthermore, we observed that trehalose effects on behaviour were associated with a reduction of the MJD-associated neuropathology. MJD transgenic mice receiving trehalose presented less atrophy of cerebellar layers, suggesting a prevention of neurodegeneration by trehalose. In agreement, an improvement of neuropathologic features was also observed in the lentiviral-based model, which expresses the full-length form of human ataxin-3. These observations are in accordance with those reported for other polyglutamine disorders. In Huntington’s disease, 2% trehalose treatment reduced foot-clasping posture and improved rotarod performance and footprint patterns of R6/2 transgenic mice [20]. These animals also displayed a reduction in striatum atrophy and in aggregate number. Similarly, treatment of SCA17 transgenic mice with 4% trehalose increased latency to fall in the rotarod and mediated amelioration of gait disturbances in the footprint analysis [37].

Neuronal intranuclear inclusions detected in the brain of patients with MJD are considered an important hallmark of the disease [3, 4, 38]. A reduction in the number of inclusions by trehalose has been reported in models of polyQ diseases and associated with improvements of the disease phenotype [15, 16, 19, 39], however this effect has not been consistently observed [37, 40, 41]. In a SCA17 mouse model, trehalose significantly improved animal’s behaviour, but had no significant effect in aggregate number [37]. Similarly, we did not detect differences in the number of aggregates of trehalose-treated animals. However, we observed a significant reduction in aggregates size after trehalose administration. The role of aggregation in the neuropathology of polyQ diseases remains controversial and the presence of mutant protein inclusions seems to not fully explain the toxicity seen in patients and mouse models [42, 43]. Even though aggregates fragments and oligomers have been considered toxic species, many studies suggest that the type of aggregates and its conformation are likely to play a more critical role in toxicity due to ability to differently sequester proteins and components, independently of their size [42,43,44,45]. Accordingly, we previously demonstrated that larger aggregates presented increased co-localization with caspase-3, suggesting an increased cytotoxicity compared to smaller aggregates [46].

Increasing amount of evidence show that trehalose exerts its neuroprotective effects by several mechanisms. Trehalose was detected in brain homogenates of mice treated with 2% trehalose in the drinking water [20, 47], which support the hypothesis of a direct effect in the brain, probably by inducing autophagy via the lysosomal-mediated TFEB activation [48,49,50]. By activating autophagy, trehalose seems to induce the clearance of unfolded proteins and oligomers, preventing or delaying the formation of larger inclusions [14]. In our experiments, we did not observe changes in autophagy markers after 2 weeks administration of 2% trehalose in the lentiviral-based model. This was not surprising, as one of the main challenges in the autophagy field is the lack of reliable tools to monitor autophagy activity in vivo. Autophagy is a highly dynamic, multi-step process and can be modulated at several steps [51] and the static analysis of LC3BII or p62 levels have limitations in capturing this dynamic process. For instance, a concomitant rise in both autophagosome formation rate and LC3-downstream degradation can show normal steady-state levels in LC3II protein despite increased autophagy activity. Thus, the use of autophagy markers in this study needs to be further complemented in other studies that estimate overall autophagic flux to allow a definitive interpretation of the observations, as stated in autophagy guidelines [52].

It is noteworthy that despite the presence of trehalase in the gut, orally administered trehalose has been proven to exert significant biological effects in mouse models of many different diseases, such as Parkinson’s, Alzheimer’s, muscular dystrophy, Huntington’s disease, ALS, prion’s disease, OPMD, obesity, hepatic steatosis, diabetes, or chronic ischemia [35, 53, 54]. Thus, we cannot exclude that trehalose effects might occur, or at least count with contribution of indirect effects in peripheral energy metabolism and inflammatory pathways [55, 56]. Therapeutic strategies that improves metabolism energy and inflammation, such as caloric restriction [22] and ibuprofen [57], are indeed effective in MJD mouse models. Interestingly, trehalose can also affect gut microbioma [58] , which raise the hypothesis that trehalose might interfere by modulating the microbiota-gut-brain axis. Further studies would be of utmost importance to clarify the mechanism of action of trehalose in MJD and other neurodegenerative disorders.

Another relevant aspect concerns the magnitude of the beneficial effects of trehalose. When compared to other molecules, the effects of trehalose in this MJD model seem to be less pronounced and less significant [22, 46]. This might be related to the high variability observed between animals, the low number of animals used (a major limitation of this study) and/or the use of a low dosage. Even though this 2% trehalose dose has been previously used in animal models [14, 17, 20, 59], administration of a higher dose of trehalose is well tolerated [37] and would likely lead to more pronounced effects in this severe animal model. Furthermore, initiating the treatment at an early stage would likely be advantageous, as it was shown for other drugs [60].

Nevertheless, our data does not support an effect comparable to our most robust approaches, namely gene silencing [9] or caloric restriction [22] or other promising strategies, such as antisense oligonucleotides [61, 62]. An interesting approach could be the use trehalose in combination with these therapies.

The major advantage supporting the use of trehalose in MJD is related to its safety. Acute and subchronic toxicological studies demonstrated that trehalose has no significant toxic effects in both animals and humans [63]. Despite being a sugar, trehalose has no adverse effects on metabolism [59, 63,64,65]. Some studies even reported a positive effect of trehalose against weight loss in mice [16, 20], which would constitute an advantage as MJD patients have decreased body mass index [66, 67]. A Phase 2 open label trial to access safety, tolerability and efficacy of trehalose in MJD patients is on-going.

In a phase 2 clinical trial to treat Oculopharyngeal Muscular Dystrophy (OPMD), trehalose was administered by intravenous injection, and despite the high dose used, no safety issues were identified [68]. More relevant, a post hoc analysis of the cold water, nectar and honey-thickened drinking tests showed that OPMD patients had a significant reduction in drinking time as compared to baseline (NCT02015481). This clinical study confirmed data from animal models [17] and brought expectations regarding the use of trehalose in protein-aggregation pathologies.

Conclusions

In conclusion, this study shows that trehalose alleviates motor impairments and neuropathological features in MJD mouse models. Further studies would be important to clarify the mechanism of neuroprotection by trehalose in MJD, to determine the most effective dose and evaluate the potential of its association with other therapeutic approaches. Nevertheless, given the favorable safety profile of trehalose this molecule has potential to be used as a pharmacological drug for MJD, alone or in combination with other therapies.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

DARPP-32:

Dopamine- and cAMP-regulated neuronal phosphoprotein

DTT:

Dithiothreitol

HA:

Hemagglutinin

LC3B:

Microtubule-associated proteins 1A/1B light chain 3B

MJD:

Machado–Joseph Disease

MutAtx-3:

Mutant ataxin-3

PBS:

Phosphate buffered saline

PFA:

Paraformaldehyde

RIPA:

Radioimmunoprecipitation assay

SDS:

Sodium dodecyl sulfate

References

  1. 1.

    Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291–304.

    PubMed  Article  Google Scholar 

  2. 2.

    Ranum LP, Lundgren JK, Schut LJ, Ahrens MJ, Perlman S, Aita J, Bird TD, Gomez C, Orr HT. Spinocerebellar ataxia type 1 and Machado–Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet. 1995;57:603–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19:333–44.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Schmidt T, Landwehrmeyer GB, Schmitt I, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol Zurich Switz. 1998;8:669–79.

    CAS  Article  Google Scholar 

  5. 5.

    Costa M do C, Paulson HL. Toward understanding Machado–Joseph disease. Prog Neurobiol. 2012;97:239–57.

    CAS  Article  Google Scholar 

  6. 6.

    Bettencourt C, Lima M. Machado–Joseph disease: from first descriptions to new perspectives. Orphanet J Rare Dis. 2011;6:35.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Rüb U, Brunt ER, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado–Joseph disease). Curr Opin Neurol. 2008;21:111–6.

    PubMed  Article  Google Scholar 

  8. 8.

    Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, et al. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado–Joseph disease. Brain J Neurol. 2011;134:1400–15.

    Article  Google Scholar 

  9. 9.

    Nóbrega C, Nascimento-Ferreira I, Onofre I, Albuquerque D, Hirai H, Déglon N, de Almeida LP. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado–Joseph disease transgenic mice. PLoS ONE. 2013;8:e52396.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  10. 10.

    Onofre I, Mendonça N, Lopes S, Nobre R, de Melo JB, Carreira IM, Januário C, Gonçalves AF, de Almeida LP. Fibroblasts of Machado Joseph disease patients reveal autophagy impairment. Sci Rep. 2016;6:28220.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Nascimento-Ferreira I, Nóbrega C, Vasconcelos-Ferreira A, Onofre I, Albuquerque D, Aveleira C, Hirai H, Déglon N, Pereira de Almeida L. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado–Joseph disease. Brain J Neurol. 2013;136:2173–88.

    Article  Google Scholar 

  12. 12.

    Ohtake S, Wang YJ. Trehalose: current use and future applications. J Pharm Sci. 2011;100:2020–53.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology. 2003;13:17R–27R.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282:5641–52.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schätzl HM, Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009;5:361–9.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van Zundert B, Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308–20.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15:23–31.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Du J, Liang Y, Xu F, Sun B, Wang Z. Trehalose rescues Alzheimer’s disease phenotypes in APP/PS1 transgenic mice. J Pharm Pharmacol. 2013;65:1753–6.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, Beger RD, Hanig JP, Schmued LC, Paule MG. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson’s disease mouse model. Neurotoxicology. 2014;44:250–62.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004;10:148–54.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S, Oue M, Yamaguchi H, Hirai H. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008;9:393–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Cunha-Santos J, Duarte-Neves J, Carmona V, Guarente L, Pereira de Almeida L, Cavadas C. Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway. Nat Commun. 2016;7:11445.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Romero-Calvo I, Ocón B, Martínez-Moya P, Suárez MD, Zarzuelo A, Martínez-Augustin O, de Medina FS. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 2010;401:318–20.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol. 2010;221:117–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Aveleira CA, Botelho M, Carmo-Silva S, et al. Neuropeptide Y stimulates autophagy in hypothalamic neurons. Proc Natl Acad Sci USA. 2015;112:E1642–51.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Lazic SE. Why we should use simpler models if the data allow this: relevance for ANOVA designs in experimental biology. BMC Physiol. 2008;8:16.

    PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Duarte-Neves J, Gonçalves N, Cunha-Santos J, Simões AT, den Dunnen WFA, Hirai H, Kügler S, Cavadas C, Pereira de Almeida L. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado–Joseph disease. Hum Mol Genet. 2015;24:5451–63.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    França MC, D’Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability abnormalities in Machado–Joseph disease. Arch Neurol. 2008;65:525–9.

    PubMed  Article  Google Scholar 

  29. 29.

    Onodera O, Idezuka J, Igarashi S, et al. Progressive atrophy of cerebellum and brainstem as a function of age and the size of the expanded CAG repeats in the MJD1 gene in Machado–Joseph disease. Ann Neurol. 1998;43:288–96.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex N Y N. 1995;5:307–22.

    CAS  Article  Google Scholar 

  31. 31.

    Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry. 2003;53:1086–98.

    PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Switonski PM, Szlachcic WJ, Krzyzosiak WJ, Figiel M. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Neurobiol Dis. 2015;73:174–88.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Marcelo A, Brito F, Carmo-Silva S, Matos CA, Alves-Cruzeiro J, Vasconcelos-Ferreira A, Koppenol R, Mendonça L, de Almeida LP, Nóbrega C. Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado–Joseph disease models. Hum Mol Genet. 2019;28:51–63.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Crowe DJH. Trehalose as a “chemical chaperone”. In: Csermely P, Vígh L, editors. Mol. asp. stress response chaperones membr. netw. Berlin: Springer; 2007. p. 143–58.

    Google Scholar 

  35. 35.

    Emanuele E. Can trehalose prevent neurodegeneration? Insights from experimental studies. Curr Drug Targets. 2014;15:551–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  36. 36.

    Ito M. Historical review of the significance of the cerebellum and the role of Purkinje cells in motor learning. Ann N Y Acad Sci. 2002;978:273–88.

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Chen Z-Z, Wang C-M, Lee G-C, Hsu H-C, Wu T-L, Lin C-W, Ma C-K, Lee-Chen G-J, Huang H-J, Hsieh-Li HM. Trehalose attenuates the gait ataxia and gliosis of spinocerebellar ataxia type 17 mice. Neurochem Res. 2015;40:800–10.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Nguyen HP, Hübener J, Weber JJ, Grueninger S, Riess O, Weiss A. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in spinocerebellar ataxia type 3 mice. PLoS ONE. 2013;8:e62043.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Zhang X, Chen S, Song L, Tang Y, Shen Y, Jia L, Le W. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10:588–602.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Seki T, Abe-Seki N, Kikawada T, Takahashi H, Yamamoto K, Adachi N, Tanaka S, Hide I, Saito N, Sakai N. Effect of trehalose on the properties of mutant {gamma}PKC, which causes spinocerebellar ataxia type 14, in neuronal cell lines and cultured Purkinje cells. J Biol Chem. 2010;285:33252–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Béranger F, Crozet C, Goldsborough A, Lehmann S. Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun. 2008;374:44–8.

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? what is toxicity? Where are we going? J Mol Cell Biol. 2010;2:180–91.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Holmes WM, Klaips CL, Serio TR. Defining the limits: protein aggregation and toxicity in vivo. Crit Rev Biochem Mol Biol. 2014;49:294–303.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Todd TW, Lim J. Aggregation formation in the polyglutamine diseases: protection at a cost? Mol Cells. 2013;36:185–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55–66.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Simões AT, Gonçalves N, Nobre RJ, Duarte CB, Pereira de Almeida L. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado–Joseph disease. Hum Mol Genet. 2014;23:4932–44.

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Lotfi P, Tse DY, Di Ronza A, Seymour ML, Martano G, Cooper JD, Pereira FA, Passafaro M, Wu SM, Sardiello M (2018) Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. Autophagy 14(8):1419–1434

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Palmieri M, Pal R, Nelvagal HR, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017. https://doi.org/10.1038/ncomms14338.

    Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Huang J, Wang X, Zhu Y, Li Z, Zhu Y-T, Wu J-C, Qin Z-H, Xiang M, Lin F. Exercise activates lysosomal function in the brain through AMPK-SIRT1-TFEB pathway. CNS Neurosci Ther. 2019;25:796–807.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Rusmini P, Cortese K, Crippa V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2018;15:631–51.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51.

    Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.

    PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Zhang Y, DeBosch BJ. Using trehalose to prevent and treat metabolic function: effectiveness and mechanisms. Curr Opin Clin Nutr Metab Care. 2019;22:303–10.

    PubMed  Article  Google Scholar 

  54. 54.

    Khalifeh M, Barreto GE, Sahebkar A. Trehalose as a promising therapeutic candidate for the treatment of Parkinson’s disease. Br J Pharmacol. 2019;176:1173–89.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Arai C, Miyake M, Matsumoto Y, et al. Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance in mice with established obesity. J Nutr Sci Vitaminol. 2013;59:393–401.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Lee H-J, Yoon Y-S, Lee S-J. Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis. 2018;9:712.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  57. 57.

    Mendonça LS, Nóbrega C, Tavino S, Brinkhaus M, Matos C, Tomé S, Moreira R, Henriques D, Kaspar BK, Pereira de Almeida L. Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado–Joseph disease models. Hum Mol Genet. 2019;28:3691–703.

    PubMed  Article  Google Scholar 

  58. 58.

    Moon JE, Heo W, Lee SH, Lee SH, Lee HG, Lee JH, Kim YJ (2020) Trehalose protects the probiotic yeast saccharomyces boulardii against oxidative stress-induced cell death. J Microbiol Biotechnol 30 (1):54–61

    PubMed  Article  Google Scholar 

  59. 59.

    Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain J Neurol. 2012;135:2169–77.

    Article  Google Scholar 

  60. 60.

    Esteves S, Oliveira S, Duarte-Silva S, Cunha-Garcia D, Teixeira-Castro A, Maciel P. Preclinical evidence supporting early initiation of citalopram treatment in Machado–Joseph disease. Mol Neurobiol. 2019;56:3626–37.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, Zhao H, Kordasiewicz HB, Shakkottai VG, Paulson HL. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol. 2018;84:64–77.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Kourkouta E, Weij R, González-Barriga A, et al. Suppression of mutant protein expression in SCA3 and SCA1 mice using a CAG repeat-targeting antisense oligonucleotide. Mol Ther Nucleic Acids. 2019;17:601–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Richards AB, Krakowka S, Dexter LB, Schmid H, Wolterbeek APM, Waalkens-Berendsen DH, Shigoyuki A, Kurimoto M. Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem Toxicol. 2002;40:871–98.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    van Can JGP, van Loon LJC, Brouns F, Blaak EE. Reduced glycaemic and insulinaemic responses following trehalose and isomaltulose ingestion: implications for postprandial substrate use in impaired glucose-tolerant subjects. Br J Nutr. 2012;108:1210–7.

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Lim Y-M, Lim H, Hur KY, et al. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. Nat Commun. 2014;5:4934.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Yang J-S, Chen P-P, Lin M-T, et al. Association between body mass index and disease severity in chinese spinocerebellar ataxia type 3 patients. Cerebellum Lond Engl. 2018;17:494–8.

    Article  Google Scholar 

  67. 67.

    Saute JAM, da Silva ACF, Souza GN, Russo AD, Donis KC, Vedolin L, Saraiva-Pereira ML, Portela LVC, Jardim LB. Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients. Cerebellum Lond Engl. 2012;11:771–4.

    CAS  Article  Google Scholar 

  68. 68.

    Argov Z, Vornovitsky H, Blumen S, Caraco Y. First human use of high dose IV trehalose: safety, tolerability and pharmacokinetic results from the oculopharyngeal muscular dystrophy (OPMD) therapy trial (P7.068). Neurology. 2015;84(P7):068.

    Google Scholar 

Download references

Acknowledgements

We thank to all the members of Vectors and Gene Therapy Group (CNC, University of Coimbra, Coimbra, Portugal) for their help in the development of this work.

Funding

This work was funded by BioBlast Pharma, the ERDF through the Regional Operational Program Center 2020, Competitiveness Factors Operational Program (COMPETE 2020) and National Funds through FCT (Foundation for Science and Technology) - SFRH/BD/87404/2012, BrainHealth2020 projects (CENTRO-01-0145-FEDER-000008), ViraVector (CENTRO-01-0145-FEDER-022095), CortaCAGs (POCI-01-0145-FEDER-016719), SpreadSilencing POCI-01-0145-FEDER-029716 and POCI-01-0145-FEDER-007440, as well as the SynSpread, ESMI and ModelPolyQ under the EU Joint Program-Neurodegenerative Disease Research (JPND), the last two co-funded by the European Union H2020 program, GA No. 643417; by National Ataxia Foundation (USA), the American Portuguese Biomedical Research Fund (APBRF) and the Richard Chin and Lily Lock Machado–Joseph Disease Research Fund.

Author information

Author notes

  1. Clévio Nóbrega

    Present address: Department of Biomedical Sciences and Medicine, Centre for Biomedical Research (CBMR), Algarve Biomedical Center (ABC), University of Algarve, Faro, Portugal

Affiliations

  1. CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 3004-504, Coimbra, Portugal

    Magda M. Santana, Susana Paixão, Janete Cunha-Santos, Teresa Pereira Silva, Allyson Trevino-Garcia, Laetitia S. Gaspar, Clévio Nóbrega, Rui Jorge Nobre, Cláudia Cavadas & Luís Pereira de Almeida

  2. CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal

    Magda M. Santana, Janete Cunha-Santos, Teresa Pereira Silva, Allyson Trevino-Garcia, Laetitia S. Gaspar, Clévio Nóbrega, Rui Jorge Nobre, Cláudia Cavadas & Luís Pereira de Almeida

  3. IIIUC - Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal

    Magda M. Santana, Laetitia S. Gaspar & Rui Jorge Nobre

  4. Bioblast Pharma, Tel Aviv, Israel

    Hagar Greif

  5. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

    Cláudia Cavadas & Luís Pereira de Almeida

Authors
  1. Magda M. Santana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susana Paixão
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janete Cunha-Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teresa Pereira Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Allyson Trevino-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laetitia S. Gaspar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Clévio Nóbrega
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rui Jorge Nobre
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cláudia Cavadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hagar Greif
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Luís Pereira de Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MMS—study plan and design, data collection (behavior experiments, cell culture, western blot, RT-qPCR, immunohistochemistry—in vitro, transgenic and lentiviral models), data analysis and interpretation, statistical analysis and manuscript writing. SP—data collection and analysis (behavior experiments and immunohistochemistry—transgenic model), manuscript writing. JC—data collection, analysis and discussion (behavior experiments, cell culture, western blot and immunohistochemistry - in vitro and transgenic models). TS—data collection and analysis (behavior experiments—transgenic model). AT—data collection and analysis (cell culture and western blot—in vitro model). LG—data collection and analysis (cell culture and RT-qPCR—in vitro model). CN—data collection, study design and data discussion (lentiviral model). RN—data collection, analysis and discussion (lentiviral model). CC—study design and data discussion. HG—study plan and design, data interpretation and discussion, manuscript writing. LPdA—study plan and design, data interpretation and discussion, manuscript writing and final approval. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Luís Pereira de Almeida.

Ethics declarations

Ethics approval and consent to participate

All experimental procedures with animals were performed in accordance with the European Union Directive 86/609/EEC for the care and use of laboratory animals. This study is part of a research project which was approved by the Center for Neuroscience and Cell Biology ethics committee (ORBEA_66_2015_/22062015) and the Portuguese Authority responsible for the regulation of animal experimentation, Direcção Geral da Agricultura e Veterinária (DGAV 0421/000/000/2015).

Consent for publication

Not applicable.

Competing interests

Luís Pereira de Almeida reports grants from BioBlast Pharma during the conduct of the study. Hagar Greif was an employee at Bioblast Pharma during the course of the work. All the other authors have nothing to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Santana, M.M., Paixão, S., Cunha-Santos, J. et al. Trehalose alleviates the phenotype of Machado–Joseph disease mouse models. J Transl Med 18, 161 (2020). https://doi.org/10.1186/s12967-020-02302-2

Download citation

Keywords

  • Machado-Joseph disease
  • Spinocerebellar ataxia type 3
  • Polyglutamine disorder
  • Trehalose
  • Autophagy

Journal of Translational Medicine

ISSN: 1479-5876

Contact us